참고문헌
- Ali S, Ahmad A, Banerjee S, et al (2010). Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res, 70, 3606-17. https://doi.org/10.1158/0008-5472.CAN-09-4598
- Bleckmann A, Siam L, Klemm F, et al (2013). Nuclear LEF1/TCF4 correlate with poor prognosis but not with nuclear beta-catenin in cerebral metastasis of lung adenocarcinomas. Clin Exp Metastasis, 30, 471-82. https://doi.org/10.1007/s10585-012-9552-7
- Chen KG, Sikic BI (2012). Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin Cancer Res, 18, 1863-9. https://doi.org/10.1158/1078-0432.CCR-11-1590
- de Sousa Cavalcante L, Monteiro G (2014). Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol, 741, 8-16. https://doi.org/10.1016/j.ejphar.2014.07.041
- Firoz A, Malik A, Singh SK, et al (2014). Comparative analysis of glycogene expression in different mouse tissues using RNA-Seq data. Int J Genomics, 2014, 837365.
- Foo J, Michor F (2014). Evolution of acquired resistance to anti-cancer therapy. J Theor Biol, 355, 10-20. https://doi.org/10.1016/j.jtbi.2014.02.025
- Griesmann H, Ripka S, Pralle M, et al (2013). WNT5A-NFAT signaling mediates resistance to apoptosis in pancreatic cancer. Neoplasia, 15, 11-22. https://doi.org/10.1593/neo.121312
- Gupta A, Schulze TG, Nagarajan V, et al (2012). Interaction networks of lithium and valproate molecular targets reveal a striking enrichment of apoptosis functional clusters and neurotrophin signaling. Pharmacogenomics J, 12, 328-41. https://doi.org/10.1038/tpj.2011.9
- Hung SW, Mody HR, Govindarajan R (2012). Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge. Cancer Lett, 320, 138-49. https://doi.org/10.1016/j.canlet.2012.03.007
- Khan S, Ebeling MC, Zaman MS, et al (2014). MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. Oncotarget, 5, 7599-609. https://doi.org/10.18632/oncotarget.2281
- Koyama-Nasu R, Nasu-Nishimura Y, Todo T, et al (2013). The critical role of cyclin D2 in cell cycle progression and tumorigenicity of glioblastoma stem cells. Oncogene, 32, 3840-5. https://doi.org/10.1038/onc.2012.399
- Li J, Wood WH, 3rd, Becker KG, et al (2007). Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells. Oncogene, 26, 2860-72. https://doi.org/10.1038/sj.onc.1210086
- Lin Q, Chen T, Lin Q, et al (2013). Serum miR-19a expression correlates with worse prognosis of patients with non-small cell lung cancer. J Surg Oncol, 107, 767-71. https://doi.org/10.1002/jso.23312
- Longley DB, Johnston PG (2005). Molecular mechanisms of drug resistance. J Pathol, 205, 275-92. https://doi.org/10.1002/path.1706
- McLachlan E, Shao Q, Wang HL, et al (2006). Connexins act as tumor suppressors in three-dimensional mammary cell organoids by regulating differentiation and angiogenesis. Cancer Res, 66, 9886-94. https://doi.org/10.1158/0008-5472.CAN-05-4302
- Mini E, Nobili S, Caciagli B, et al (2006). Cellular pharmacology of gemcitabine. Ann Oncol, 17, 7-12.
- Molina-Navarro MM, Trivino JC, Martinez-Dolz L, et al (2014). Functional networks of nucleocytoplasmic transport-related genes differentiate ischemic and dilated cardiomyopathies. A new therapeutic opportunity. PLoS One, 9, 104709. https://doi.org/10.1371/journal.pone.0104709
- Nakano Y, Tanno S, Koizumi K, et al (2007). Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer, 96, 457-63. https://doi.org/10.1038/sj.bjc.6603559
- Nepusz T, Yu H, Paccanaro A (2012). Detecting overlapping protein complexes in protein-protein interaction networks. Nat Methods, 9, 471-2. https://doi.org/10.1038/nmeth.1938
- Nguyen DX, Chiang AC, Zhang XH, et al (2009). WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell, 138, 51-62. https://doi.org/10.1016/j.cell.2009.04.030
- Pan XH (2012). Pathway crosstalk analysis based on protein-protein network analysis in ovarian cancer. Asian Pac J Cancer Prev, 13, 3905-9. https://doi.org/10.7314/APJCP.2012.13.8.3905
- Saiki Y, Yoshino Y, Fujimura H, et al (2012). DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells. Biochem Biophys Res Commun, 421, 98-104. https://doi.org/10.1016/j.bbrc.2012.03.122
- Saraswathy M, Gong S (2013). Different strategies to overcome multidrug resistance in cancer. Biotechnol Adv, 31, 1397-407. https://doi.org/10.1016/j.biotechadv.2013.06.004
- Shi WY, Liu KD, Xu SG, et al (2014). Gene expression analysis of lung cancer. Eur Rev Med Pharmacol Sci, 18, 217-28.
- Song GG, Kim JH, Seo YH, et al (2014). Meta-analysis of differentially expressed genes in primary Sjogren's syndrome by using microarray. Hum Immunol, 75, 98-104.
- Szakacs G, Paterson JK, Ludwig JA, et al (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Discov, 5, 219-34. https://doi.org/10.1038/nrd1984
- Teraishi F, Zhang L, Guo W, et al (2005). Activation of c-Jun NH2-terminal kinase is required for gemcitabine's cytotoxic effect in human lung cancer H1299 cells. FEBS Lett, 579, 6681-7. https://doi.org/10.1016/j.febslet.2005.10.064
- Tooker P, Yen WC, Ng SC, et al (2007). Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. Cancer Res, 67, 4425-33. https://doi.org/10.1158/0008-5472.CAN-06-4495
- Toro-Dominguez D, Carmona-Saez P, Alarcon-Riquelme ME (2014). Shared signatures between rheumatoid arthritis, systemic lupus erythematosus and Sjogren inverted question marks syndrome uncovered through gene expression metaanalysis. Arthritis Res Ther, 16, 489. https://doi.org/10.1186/s13075-014-0489-x
- Toschi L, Cappuzzo F (2009). Gemcitabine for the treatment of advanced nonsmall cell lung cancer. Onco Targets Ther, 2, 209-17.
- Toschi L, Finocchiaro G, Bartolini S, et al (2005). Role of gemcitabine in cancer therapy. Future Oncol, 1, 7-17. https://doi.org/10.1517/14796694.1.1.7
- Tufman A, Huber RM (2010). Biological markers in lung cancer: A clinician's perspective. Cancer Biomark, 6, 123-35.
- Warde-Farley D, Donaldson SL, Comes O, et al (2010). The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res, 38, W214-20. https://doi.org/10.1093/nar/gkq537
- Xia J, Fjell CD, Mayer ML, et al (2013). INMEX--a web-based tool for integrative meta-analysis of expression data. Nucleic Acids Res, 41, 63-70. https://doi.org/10.1093/nar/gks1029
- Zhang X, Jin FS, Zhang LG, et al (2013). Predictive and prognostic roles of ribonucleotide reductase M1 in patients with pancreatic cancer treated with gemcitabine: a meta-analysis. Asian Pac J Cancer Prev, 14, 4261-5. https://doi.org/10.7314/APJCP.2013.14.7.4261